Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of venetoclax plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
CTR20210070Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax, azacitidine in myelodysplastic syndrome (MDS), sponsored by AbbVie Inc.. Started May 2021; status: active.
02
Drugs
venetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20210070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210070.